Evidence map›Paper›PMID 28905124›Full record

ReviewNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2018

Arthritic psoriasis during natalizumab treatment: a case report and review of the literature.

V Vacchiano, M Foschi, L Sabattini, C Scandellari, A Lugaresi

Abstract readCase ReportsLetterReview
PubMed Publisher
In one paragraph

Review in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Treatment approaches to patients with multiple sclerosis and coexisting psoriasis - A longitudinal multicenter observational cohort study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Observational
  3. Review
  4. Improvement of Comorbid Psoriasis in Patients With MS Treated With Natalizumab.Neurology(R) neuroimmunology & neuroinflammation · 2021
    Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

V VacchianoDepartment of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
M FoschiDepartment of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy.
L SabattiniIRCCS Institute of the Neurological Sciences of Bologna (ISNB), Bologna, Italy.
C ScandellariIRCCS Institute of the Neurological Sciences of Bologna (ISNB), Bologna, Italy.
A LugaresiDepartment of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy. alessandra.lugaresi2@unibo.it.
Istituti di Ricovero e Cura a Carattere Scientifico · ITUniversity of Bologna · ITInstitute of Neurological Sciences · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Arthritis, PsoriaticFemaleHumansImmunologic FactorsMiddle AgedMultiple Sclerosis, Relapsing-RemittingNatalizumabImmunologic FactorsNatalizumab

Identifiers

PMID28905124
OpenAlexW2756388901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.